1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Eli Lilly and Company - Strategy and SWOT Report

Eli Lilly and Company - Strategy and SWOT Report

  • November 2015
  • -
  • MarketLine
  • -
  • 39 pages

Introduction

Eli Lilly and Company - Strategy and SWOT Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360? view of the company.

Features:

- Detailed information on Eli Lilly and Company required for business and competitor intelligence needs

- A study of the major internal and external factors affecting Eli Lilly and Company in the form of a SWOT analysis

- An in-depth view of the business model of Eli Lilly and Company including a breakdown and examination of key business segments

- Intelligence on Eli Lilly and Company’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors

- News about Eli Lilly and Company, such as business expansion, restructuring, and contract wins

- Large number of easy-to-grasp charts and graphs that present important data and key trends

Highlights:

Eli Lilly and Company (Lilly or 'the company') is engaged in developing, manufacturing, and marketing pharmaceutical products and animal health products. The company operates in the US, Japan, Europe and other countries. It is headquartered in Indianapolis, Indiana, and employed 39,135 people as on December 31, 2014. The company recorded revenues of $19,615.6 million during the financial year ended December 2014 (FY2014), a decrease of 15.1% compared with FY2013. The operating profit of the company was $2,659.8 million* in FY2014, a decrease of 50.5% compared with FY2013. The net profit of the company was $2,390.5 million in FY2014, a decrease of 49% compared with FY2013. *Earnings before interest and tax.

Reasons to Purchase:

- Gain understanding of Eli Lilly and Company and the factors that influence its strategies

- Track strategic initiatives of the company and latest corporate news and actions

- Assess Eli Lilly and Company as a prospective partner, vendor or supplier

- Support sales activities by understanding your customers' businesses better

- Stay up to date on Eli Lilly and Company’s business structure, strategy and prospects

Table Of Contents

Eli Lilly and Company - Strategy and SWOT Report
Company Overview
Business Description
History
Key Employees and Biographies
Company View
Locations and Subsidiaries
SWOT Analysis
Revenue Analysis
Key Competitors
Major Products and Services

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016’, provides in depth analysis ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.